Cullinan Mica Overview
- Year Founded
-
2015
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
- Investors
-
2
Cullinan Mica General Information
Description
Developer of a monoclonal antibody designed to reinvigorate the axis into human clinical testing. The company's antibody is predicated on distributing risk while maximizing the optionality inherent in novel science through the construction of a diversified portfolio of internally developed as well as externally sourced oncology assets, enabling physicians to broadly engage natural killer cells and certain lymphocyte populations for tumor cell lysis.
Contact Information
Corporate Office
- One Main Street
- Suite 520
- Cambridge, MA 02142
- United States
Corporate Office
- One Main Street
- Suite 520
- Cambridge, MA 02142
- United States
Cullinan Mica Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | 12-Apr-2024 | Completed | Startup | |||
| 3. Secondary Transaction - Private | 25-Oct-2022 | Completed | Startup | |||
| 2. Later Stage VC | 21-Mar-2022 | $10M | $36M | Completed | Startup | |
| 1. Later Stage VC (Series A) | 11-Jun-2020 | $26M | $26M | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Cullinan Mica Patents
Cullinan Mica Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024277733-A1 | Methods of treating cancer with anti-mica/b antibodies | Pending | 24-May-2023 | ||
| EP-4720128-A2 | Methods of treating cancer with anti-mica/b antibodies | Inactive | 24-May-2023 | ||
| US-20260317426-A1 | Methods of treating cancer with anti-mica/b antibodies | Pending | 24-May-2023 | ||
| WO-2024243255-A2 | Methods of treating cancer with anti-mica/b antibodies | Inactive | 24-May-2023 | ||
| WO-2024243255-A3 | Methods of treating cancer with anti-mica/b antibodies | Inactive | 24-May-2023 | C07K16/2833 |
Cullinan Mica Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cullinan Therapeutics | Corporation | Minority | ||
| MMRF Venture | Venture Capital | Minority |
Cullinan Mica FAQs
-
When was Cullinan Mica founded?
Cullinan Mica was founded in 2015.
-
Where is Cullinan Mica headquartered?
Cullinan Mica is headquartered in Cambridge, MA.
-
What industry is Cullinan Mica in?
Cullinan Mica’s primary industry is Drug Delivery.
-
Is Cullinan Mica a private or public company?
Cullinan Mica is a Private company.
-
What is Cullinan Mica’s current revenue?
The current revenue for Cullinan Mica is .
-
How much funding has Cullinan Mica raised over time?
Cullinan Mica has raised $36M.
-
Who are Cullinan Mica’s investors?
Cullinan Therapeutics and MMRF Venture have invested in Cullinan Mica.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process